Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (12575)
All Articles published online
|
Publishing Process of This Article
|
Nov 21, 2014 (publication date) through Nov 27, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu FJ, Wu DC, Kuo FC. CYP2C19 polymorphism influences |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i43/16029.htm |
| Number | Citing Articles |
| 1 |
Lara Aguilera Castro, Carlos Martín de Argila de Prados, Agustín Albillos Martínez. Practical considerations in the management of proton-pump inhibitors. Revista Española de Enfermedades Digestivas 2015; doi: 10.17235/reed.2015.3812/2015
|
| 2 |
Shan Jing, Yue Zhu, Wenfang Liu, Kexu Yang, Lili Hu, Dan Deng, Chunyan Lu, Yang Lin. Pharmacokinetics and Pharmacodynamics of Esomeprazole/Sodium Bicarbonate Immediate-Release Capsules in Healthy Chinese Volunteers: A Cross-Over, Randomized Controlled Trial. Advances in Therapy 2021; 38(3): 1660 doi: 10.1007/s12325-021-01644-7
|
| 3 |
Jun Zhang, Jing Zhong, Jian Ding, Jiemin Shi, Tao Tang, Qiqi Liu, Huilian Huang, Licheng Dai, Ningmin Yang. Simultaneous detection of human CYP2C19 polymorphisms and antibiotic resistance of Helicobacter pylori using a personalised diagnosis kit. Journal of Global Antimicrobial Resistance 2018; 13: 174 doi: 10.1016/j.jgar.2017.12.018
|
| 4 |
Pedro Cortés, Alfred D. Nelson, Yan Bi, Fernando F. Stancampiano, Loren P. Murray, George G.A. Pujalte, Victoria Gomez, Dana M. Harris. Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review. Journal of Primary Care & Community Health 2021; 12 doi: 10.1177/21501327211014087
|
| 5 |
Natsuda Aumpan, Navapan Issariyakulkarn, Varocha Mahachai, David Graham, Yoshio Yamaoka, Ratha-korn Vilaichone, Muhammad Shahzad Aslam. Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial). PLOS ONE 2023; 18(11): e0294403 doi: 10.1371/journal.pone.0294403
|
| 6 |
He-Jian Zhang, Xue-Hui Zhang, Jie Liu, Lu-Ning Sun, Yi-Wen Shen, Chen Zhou, Hong-Wen Zhang, Li-Jun Xie, Juan Chen, Yun Liu, Yong-Qing Wang. Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors. Pharmacological Research 2020; 152: 104606 doi: 10.1016/j.phrs.2019.104606
|
| 7 |
Muhamad A. K. Shakhatreh, Omar F. Khabour, Karem H. Alzoubi, Mohammed N. BaniHani, Ahmed Abu-Siniyeh, Nabil A. Bashir, Salsabeel H. Sabi, Mahmoud Mahafdah. <p>The Influence of <em>IL-1B</em> Gene Polymorphisms on <em>H. pylori</em> Infection and Triple Treatment Response Among Jordanian Population</p>. The Application of Clinical Genetics 2020; : 139 doi: 10.2147/TACG.S253778
|
| 8 |
Wen Zhong Liu, Yong Xie, Hong Lu, Hong Cheng, Zhi Rong Zeng, Li Ya Zhou, Ye Chen, Jiang Bin Wang, Yi Qi Du, Nong Hua Lu. Fifth Chinese National Consensus Report on the management ofHelicobacter pyloriinfection. Helicobacter 2018; 23(2) doi: 10.1111/hel.12475
|
| 9 |
Shailja Shah, Elizabeth Hubscher, Corey Pelletier, Rinu Jacob, Lydia Vinals, Rena Yadlapati. Helicobacter pylori infection treatment in the United States: clinical consequences and costs of eradication treatment failure. Expert Review of Gastroenterology & Hepatology 2022; 16(4): 341 doi: 10.1080/17474124.2022.2056015
|
| 10 |
Xiaoye Shi, Chunmei Wang, Fanjun Meng, Shaoze Ma, Guangqin Xu, Tingwei Liu, Xiaozhong Guo, Hongyu Li, Xingshun Qi. Impact of insufficient doses of medications on Helicobacter pylori eradication: a retrospective observational study. Postgraduate Medicine 2022; 134(7): 668 doi: 10.1080/00325481.2022.2105094
|
| 11 |
Xiaodan Lu, Luyao Huang, Yanjun Chen, Ling Hu, Rongbin Zhong, Lijiao Chen, Wenjian Cheng, Baodong Zheng, Peng Liang. Effect of DHA-Enriched Phospholipids from Fish Roe on Rat Fecal Metabolites: Untargeted Metabolomic Analysis. Foods 2023; 12(8): 1687 doi: 10.3390/foods12081687
|
| 12 |
Chao-Hung Kuo, Chung-Jung Liu, Ching-Chia Yang, Fu-Chen Kuo, Huang-Ming Hu, Hsiang-Yao Shih, Meng-Chieh Wu, Yen-Hsu Chen, Hui-Min David Wang, Jian-Lin Ren, Deng-Chyang Wu, Lin-Li Chang. A Rapid and Accurate Method to Evaluate Helicobacter pylori Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric Juice. Medicine 2016; 95(21): e3458 doi: 10.1097/MD.0000000000003458
|
| 13 |
Malek Zihlif, Banan Bashaireh, Mohammed Rashid, Zaid Almadani, Yazun Jarrar. Effect of major CYP2C19 genetic polymorphisms on Helicobacter pylori eradication based on different treatment regimens. Biomedical Reports 2021; 16(1) doi: 10.3892/br.2021.1485
|
| 14 |
Lili Yang, Ao Zou, Huihua Wu, Hai Guo, Fangting Zhang, Bing Zou, Junping Wang, Emily Chia-Yu Su. Application of Visual Gene Clip-Based Tailored Therapy for the Eradication of Helicobacter pylori. BioMed Research International 2021; 2021: 1 doi: 10.1155/2021/6150628
|
| 15 |
Jihee Sung, Nayoung Kim, Yo Han Park, Young Jae Hwang, Soohoon Kwon, Gyeongjae Na, Joon Young Choi, Jae Bin Kang, Hye Rang Kim, Jin-Wook Kim, Dong Ho Lee. Rifabutin-based Fourth and Fifth-line Rescue Therapy in Patients with forHelicobacter pyloriEradication Failure. The Korean Journal of Gastroenterology 2017; 69(2): 109 doi: 10.4166/kjg.2017.69.2.109
|
| 16 |
Martin Klieber, Herbert Oberacher, Silvia Hofstaetter, Beate Beer, Martin Neururer, Anton Amann, Hannes Alber, Anil Modak. CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine. Journal of Pharmacology and Experimental Therapeutics 2015; 354(3): 426 doi: 10.1124/jpet.115.225680
|
| 17 |
I V Maev, D N Andreev. Molecular genetic predictors of resistance to anti-Helicobacter pylori therapy. Terapevticheskii arkhiv 2017; 89(8): 5 doi: 10.17116/terarkh20178985-12
|
| 18 |
Aktualisierte S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – Juli 2022 – AWMF-Registernummer: 021–001. Zeitschrift für Gastroenterologie 2023; 61(05): 544 doi: 10.1055/a-1975-0414
|
| 19 |
Patricio Medel‐Jara, Diego Reyes Placencia, Eduardo Fuentes‐López, Oscar Corsi, Gonzalo Latorre, Rosario Antón, Elena Jiménez, Ana Miralles‐Marco, Carmelo Caballero, Hugo Boggino, Daniel Cantero, Rita Barros, João Santos‐Antunes, Marc Díez, Luis A. Quiñones, Erick Riquelme, Antonio Rollán, Leslie C. Cerpa, Ivania Valdés, Olga P. Nyssen, Leticia Moreira, Javier P. Gisbert, M. Constanza Camargo, Nayeli Ortiz‐Olvera, Alberto M. Leon‐Takahashi, Erika Ruiz‐Garcia, Edith A. Fernández‐Figueroa, Marcelo Garrido, Gareth I. Owen, Andrés Cervantes, Tania Fleitas, Arnoldo Riquelme. Quadruple therapies show a higher eradication rate compared to standard triple therapy for Helicobacter pylori infection within the LEGACy consortium. A multicenter observational study in European and Latin American countries. United European Gastroenterology Journal 2024; 12(9): 1190 doi: 10.1002/ueg2.12605
|
| 20 |
Ji Hyun Lim, Dong Ho Lee, Seong Tae Lee, Nayoung Kim, Young Soo Park, Cheol Min Shin, In Sung Song. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for <italic>Helicobacter pylori</italic> infection. World Journal of Gastroenterology 2015; 21(46): 13124-13131 doi: 10.3748/wjg.v21.i46.13124
|
| 21 |
Álvaro Vela, Carmen Guerrero. Análisis del polimorfismo CYP2C19*2 en la población castellanoleonesa. FarmaJournal 2020; 5(1): 95 doi: 10.14201/fj20205195104
|
| 22 |
Antonio Mestrovic, Nikola Perkovic, Ante Tonkic, Zeljko Sundov, Marko Kumric, Josko Bozic. Personalized Approach in Eradication of Helicobacter pylori Infection. Antibiotics 2022; 12(1): 7 doi: 10.3390/antibiotics12010007
|
| 23 |
Hideki Mori, Hidekazu Suzuki. Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker. Journal of Neurogastroenterology and Motility 2019; 25(1): 6 doi: 10.5056/jnm18139
|
| 24 |
Siya Kong, Keting Huang, Jun Wang, Xiaoyong Wang, Ningmin Yang, Yu Dong, Ya Zhuang, Yini Dang, Guoxin Zhang, Feng Ye. Efficacy of tailored second-line therapy of Helicobacter pylori eradication in patients with clarithromycin-based treatment failure: a multicenter prospective study. Gut Pathogens 2020; 12(1) doi: 10.1186/s13099-020-00378-1
|
| 25 |
Yi Hu, Yin Zhu, Nong-Hua Lu. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Frontiers in Cellular and Infection Microbiology 2017; 7 doi: 10.3389/fcimb.2017.00168
|
| 26 |
Jeffrey Fong. PharmacotherapyFirst: A Multimedia Learning Resource. 2017; doi: 10.21019/pharmacotherapyfirst.pud_overview
|
| 27 |
Yi Song, Fengna Dou, Zhe Zhou, Ningmin Yang, Jing Zhong, Jie Pan, Qiqi Liu, Jianzhong Zhang, Shengqi Wang. Microarray-Based Detection and Clinical Evaluation for Helicobacter pylori Resistance to Clarithromycin or Levofloxacin and the Genotype of CYP2C19 in 1083 Patients. BioMed Research International 2018; 2018: 1 doi: 10.1155/2018/2684836
|
| 28 |
Xianghong Zhao, Zhongqiu Zhang, Fang Lu, Mengqiu Xiong, Liping Jiang, Ke Tang, Min Fu, Yu Wu, Bangshun He. Effects of CYP2C19 genetic polymorphisms on the cure rates of H. pylori in patients treated with the proton pump inhibitors: An updated meta-analysis. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.938419
|
| 29 |
V.I. Petrov, A.V. Ponomareva, I.V. Ivakhnenko, O.V. Razvalyaeva, A.M. Dotsenko. PROBLEMS OF ERADICATION THERAPY AND WAYSTO OVERCOME THEM: REVIEW OF MODERN RECOMMENDATIONS AND REAL PRACTICE. Journal of Volgograd State Medical University 2022; 19(4): 22 doi: 10.19163/1994-9480-2022-19-4-22-33
|
| 30 |
Jaeyoung Kim, Yeon-Ji Kim, Woo Chul Chung. Proton Pump Inhibitor Switching Strategy after Failure of Standard Triple Therapy for Helicobacter pylori Infection. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2020; 20(2): 146 doi: 10.7704/kjhugr.2019.0036
|
| 31 |
Nam Phan. Nghiên cứu kiểu gen mã hóa cyp2c19 và mối liên quan đến hiệu quả điều trị helicobacterpylori của phác đồ hai thuốc liều cao (ppi, amoxicillin). Journal of Clinical Medicine- Hue Central Hospital 2023; (85) doi: 10.38103/jcmhch.85.16
|
| 32 |
Pratsanee Hiengrach, Wimonrat Panpetch, Ariya Chindamporn, Asada Leelahavanichkul. Helicobacter pylori, Protected from Antibiotics and Stresses Inside Candida albicans Vacuoles, Cause Gastritis in Mice. International Journal of Molecular Sciences 2022; 23(15): 8568 doi: 10.3390/ijms23158568
|
| 33 |
Sotirios D Georgopoulos, Vasilios Papastergiou, Stylianos Karatapanis. Treatment ofHelicobacter Pyloriinfection: optimization strategies in a high resistance era. Expert Opinion on Pharmacotherapy 2015; 16(15): 2307 doi: 10.1517/14656566.2015.1084503
|
| 34 |
Maliheh Safavi, Reyhaneh Sabourian, Alireza Foroumadi. Treatment of <i>Helicobacter pylori</i> infection: Current and future insights. World Journal of Clinical Cases 2016; 4(1): 5-19 doi: 10.12998/wjcc.v4.i1.5
|
| 35 |
Enzo Ierardi, Giuseppe Losurdo, Rosa Federica La Fortezza, Mariabeatrice Principi, Michele Barone, Alfredo Di Leo. Optimizing proton pump inhibitors in <i>Helicobacter pylori</i> treatment: Old and new tricks to improve effectiveness. World Journal of Gastroenterology 2019; 25(34): 5097-5104 doi: 10.3748/wjg.v25.i34.5097
|
| 36 |
Xue‐Feng Zhong, Gan Zhou, Su‐Mei Xu, Xiao‐Min Li, Ying Xu, Wan‐Li Liu, Yan‐Xin Zhang, Lin‐Cong He, Qiu‐Ying Shen, Ping‐Sheng Xu. Pharmacokinetics of Esomeprazole Magnesium After Single Oral Doses in Healthy Subjects: Bioequivalence Study and Food Effects. Clinical Pharmacology in Drug Development 2022; 11(11): 1308 doi: 10.1002/cpdd.1139
|
| 37 |
You‐hua Wang, Zhi‐fa Lv, Yao Zhong, Dong‐sheng Liu, Shu‐ping Chen, Yong Xie. The internalization of Helicobacter pylori plays a role in the failure of H. pylori eradication. Helicobacter 2017; 22(1) doi: 10.1111/hel.12324
|
| 38 |
Wei-Chen Tai, I-Ting Wu, Hsin-Ming Wang, Pao-Yuan Huang, Chih-Chien Yao, Cheng-Kun Wu, Shih-Cheng Yang, Chih-Ming Liang, Pin-I Hsu, Seng-Kee Chuah. The multicenter real-world report of the efficacies of 14-day esomeprazole-based and rabeprazole-based high-dose dual therapy in first-line Helicobacter pylori eradication in Taiwan. Journal of Microbiology, Immunology and Infection 2024; 57(4): 601 doi: 10.1016/j.jmii.2024.02.009
|
| 39 |
Anil S Modak. Point-of-care companion diagnostic tests for personalizing psychiatric medications: fulfilling an unmet clinical need. Journal of Breath Research 2017; 12(1): 017101 doi: 10.1088/1752-7163/aa8d2e
|
| 40 |
A. Arenas, C. Serrano, L. Quiñones, P. Harris, M. Sandoval, M. Lavanderos, R. Sepúlveda, S. Maquilón, A. Echeverría, C. Ríos, E. Fuentes-López, L. Rojas, A. Jorquera, M. Pizarro, M. C. Camargo, A. Riquelme. High prevalence of clarithromycin resistance and effect on Helicobacter pylori eradication in a population from Santiago, Chile: cohort study and meta-analysis. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-56399-7
|
| 41 |
Cailing Li, Yanyan Shi, Baojun Suo, Xueli Tian, Liya Zhou, Zhiqiang Song. PPI‐amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta‐analysis. Helicobacter 2021; 26(4) doi: 10.1111/hel.12816
|
| 42 |
Manuel Pabón‐Carrasco, Alma Keco‐Huerga, Manuel Castro‐Fernández, Ilaria Maria Saracino, Giulia Fiorini, Dino Vaira, Ángeles Pérez‐Aísa, Bojan Tepes, Laimas Jonaitis, Irina Voynovan, Alfredo J. Lucendo, Ángel Lanas, Samuel J. Martínez‐Domínguez, Enrique Alfaro Almajano, Luis Rodrigo, Ludmila Vologzanina, Natasa Brglez Jurecic, Maja Denkovski, Luis Bujanda, Rustam A. Abdulkhakov, Jose M. Huguet, Luis Fernández‐Salazar, Noelia Alcaide, Benito Velayos, Aiman Silkanovna Sarsenbaeva, Oleg Zaytsev, Tatiana Ilchishina, Jesús Barrio, Igor Bakulin, Monica Perona, Sergey Alekseenko, Marco Romano, Antonietta G. Gravina, Óscar Núñez, Blas José Gómez Rodríguez, Diego Ledro‐Cano, Rinaldo Pellicano, Pavel Bogomolov, Manuel Domínguez‐Cajal, Pedro Almela, Judith Gomez‐Camarero, Dmitry S. Bordin, Antonio Gasbarrini, Juozas Kupčinskas, Anna Cano‐Català, Leticia Moreira, Olga P. Nyssen, Francis Mégraud, Colm O’Morain, Javier P. Gisbert. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management. United European Gastroenterology Journal 2024; 12(1): 122 doi: 10.1002/ueg2.12476
|
| 43 |
James P. Franciosi, Edward B. Mougey, Andre Williams, Roberto A. Gomez‐Suarez, Cameron Thomas, Christa L. Creech, Katherine George, Diana Corao, John J. Lima. Association BetweenCYP2C19*17Alleles and pH Probe Testing Outcomes in Children With Symptomatic Gastroesophageal Reflux. The Journal of Clinical Pharmacology 2018; 58(1): 89 doi: 10.1002/jcph.977
|
| 44 |
Hiroyuki Eto, Sho Suzuki, Chika Kusano, Hisatomo Ikehara, Ryoji Ichijima, Hirotaka Ito, Koichi Kawabe, Masashi Kawamura, Yoshioki Yoda, Moriyasu Nakahara, Takuji Gotoda. Impact of body size on first‐line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy. Helicobacter 2021; 26(2) doi: 10.1111/hel.12788
|
| 45 |
Juan Fu, Chang-Feng Sun, Hong-Yan He, Suvash Chandra Ojha, Han Shi, Cun-Liang Deng, Yun-Jian Sheng.
The Effect of
CYP2C19
Gene Polymorphism on the Eradication Rate of
Helicobacter Pylori
by Proton Pump Inhibitors-ContAining Regimens in Asian Populations: a Meta-Analysis
. Pharmacogenomics 2021; 22(13): 859 doi: 10.2217/pgs-2020-0127
|
| 46 |
Malek Shatila, Anusha Shirwaikar Thomas. Current and Future Perspectives in the Diagnosis and Management of Helicobacter pylori Infection. Journal of Clinical Medicine 2022; 11(17): 5086 doi: 10.3390/jcm11175086
|
| 47 |
Hyasinta Jaka, Andreas Mueller, Christa Kasang, Stephen E. Mshana. Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective study. BMC Infectious Diseases 2019; 19(1) doi: 10.1186/s12879-019-4085-1
|
| 48 |
Nuttapat Tungtrongchitr, Phubordee Bongkotvirawan, Sarita Ratana-Amornpin, Sith Siramolpiwat, Thanee Eiamsitrakoon, Pornpen Gamnarai, Arti Wongcha-um, Yoshio Yamaoka, Kammal Kumar Pawa, Ratha-korn Vilaichone. Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial). Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-59621-3
|
| 49 |
Daphne Ang, Seok Hwee Koo, Yiong Huak Chan, Thean Yen Tan, Gaik Hong Soon, Chin Kimg Tan, Kenneth Weicong Lin, Jaydeesh‐Khanna Krishnasamy‐Balasubramanian, Yu Jun Wong, Rahul Kumar, Rajesh R, Yiyuan Tan, Peng‐Lan Jeannie Ong, Yi‐Lyn Jessica Tan, James Weiquan Li, Andrew Boon‐Eu Kwek, Tiing Leong Ang. Clinical trial: seven‐day vonoprazan‐ versus 14‐day proton pump inhibitor‐based triple therapy for first‐line Helicobacter pylori eradication. Alimentary Pharmacology & Therapeutics 2022; 56(3): 436 doi: 10.1111/apt.17070
|
| 50 |
Kiarash Ghazvini, Hossein Kamali, Seyed-Abolfazl Hosseininasab-nodoushan, Masoud Keikha. The CYP2C19 polymorphisms effects on H. pylori cure rate in proton pump inhibitor-based therapeutic regimens: An updated meta-analysis. Gene Reports 2021; 25: 101340 doi: 10.1016/j.genrep.2021.101340
|
| 51 |
Vaneet Jearth, Manas Kumar Panigrahi. Current paradigms in the management of refractory Helicobacter pylori infection. Indian Journal of Gastroenterology 2023; 42(6): 766 doi: 10.1007/s12664-023-01448-3
|
| 52 |
Lian-Di Kan, Jie Chen, Yue-Ting Huang, Yang Qiu, Xin-Lu Yu, Hong-Mei Fang, Qin Chen, Liu-Cheng Li. Evaluation of different proton pump inhibitors combined with bismuth quadruple regimens in Helicobacter pylori eradication. Clinical and Experimental Medicine 2020; 20(4): 609 doi: 10.1007/s10238-020-00643-2
|
| 53 |
Azucena Arévalo Galvis, Alba Alicia Trespalacios Rangel, William Otero Regino. Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first‐line triple therapy. Helicobacter 2019; 24(3) doi: 10.1111/hel.12574
|
| 54 |
Natalia V. Bakulina, Sergey V. Tikhonov, Anastasia Yu. Efremova, Vakhtang V. Mirtskhulava. Features of GERD therapy in obese patients: A review. Consilium Medicum 2023; 25(5): 361 doi: 10.26442/20751753.2023.5.202289
|
| 55 |
Regis R Vieira, Luís Eduardo S Fontes, Rafael L Pacheco, Marcos AP Fernandes, Paloma P Malta, Rachel Riera. Proton pump inhibitor- and clarithromycin-based triple therapies for Helicobacter pylori eradication. Cochrane Database of Systematic Reviews 2020; 2021(8) doi: 10.1002/14651858.CD013734
|
| 56 |
Atena Abedi Maghami, Ashraf Mohabati Mobarez, Abbas Yadegar, Maryam Nikkhah, Amir Sadeghi, Saber Esmaeili. Assessment of Helicobacter pylori positive infected patients according to Clarithromycin resistant 23S rRNA, rpl22 associated mutations and cyp2c19*1, *2, *3 genes pattern in the Early stage of Gastritis. BMC Research Notes 2022; 15(1) doi: 10.1186/s13104-022-06227-5
|
| 57 |
Danli Zhou, Wuyu Wang, Lan Gu, Meiling Han, Wujuan Hao, Junfeng Huang, Qiong Lin, Yan Wang. Helicobacter pylori antibiotic resistance profile in Chinese children with upper gastrointestinal symptoms and a literature review for developing personalized eradicating strategies. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1392787
|
| 58 |
Delaney Provenza, John Michael Provenza. Vonoprazan. JAAPA 2024; 37(12): 13 doi: 10.1097/01.JAA.0000000000000154
|
| 59 |
Chao Ran Ji, Jing Liu, Yue Yue Li, Chen Qiao, Jun Yan Qu, Jun Nan Hu, Min Juan Lin, Rui Ji, Li Xiang Li, Xiu Li Zuo, Yan Qing Li. Susceptibility‐guided quadruple therapy is not superior to medication history‐guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial. Journal of Digestive Diseases 2020; 21(10): 549 doi: 10.1111/1751-2980.12934
|
| 60 |
Valerie Josephine Dirjayanto, Jessica Audrey, Daniel Martin Simadibrata. Vonoprazan-amoxicillin dual regimen with <i>Saccharomyces boulardii</i> as a rescue therapy for <i>Helicobacter pylori</i>: Current perspectives and implications. World Journal of Gastroenterology 2024; 30(10): 1280-1286 doi: 10.3748/wjg.v30.i10.1280
Abstract(364) |
Core Tip(403) |
Full Article(HTML)(2125)
|
Full Article with Cover (PDF)-823K(101)
|
Full Article (Word)-173K(0)
|
Audio-1404K(6)
|
Peer-Review Report-216K(35)
|
Answering Reviewers-96K(34)
|
Full Article (PDF)-570K(116)
|
Full Article (XML)-94K(33)
|
Times Cited (1)
|
Total Visits (4200)
|
Open
|
| 61 |
Paulius Jonaitis, Juozas Kupcinskas, Javier P. Gisbert, Laimas Jonaitis. Helicobacter pylori Eradication Treatment in Older Patients. Drugs & Aging 2024; 41(2): 141 doi: 10.1007/s40266-023-01090-w
|
| 62 |
Azza Abbas, Sawazen Malik, Bushra Sulieman, Khalid Enan. Detection of CYP2C19*2_ allele among Helicobacter pylori -infected patients in two tertiary hospitals of Khartoum, Sudan, 2019. F1000Research 2021; 10: 1063 doi: 10.12688/f1000research.73724.1
|
| 63 |
Wei-Chen Tai, Shih-Cheng Yang, Chih-Chien Yao, Cheng-Kun Wu, An-Che Liu, Chen-Hsiang Lee, Yuan-Hung Kuo, Seng-Kee Chuah, Chih-Ming Liang. The Efficacy and Safety of 14-day Rabeprazole Plus Amoxicillin High Dose Dual Therapy by Comparing to 14-day Rabeprazole-Containing Hybrid Therapy for the Naïve Helicobacter pylori Infection in Taiwan: A Randomized Controlled Trial. Infectious Diseases and Therapy 2023; 12(5): 1415 doi: 10.1007/s40121-023-00811-3
|
| 64 |
Mohammed N. BaniHani, Omar F. Khabour, Karem H. Alzoubi, Nabil A. Bashir, Muhamad Ali K. Shakhatreh, Salsabeel H. Sabi, Nasr Alrabadi. The Association between ABCB1 C1236T/C3435T SNPs and H. pylori Infection among Jordanians. Genes 2020; 11(1): 63 doi: 10.3390/genes11010063
|
| 65 |
Kenta Sakaguchi, Takafumi Naito, Kohei Hoshikawa, Yukari Miyadera, Hironari Tanaka, Emi Nakatsugawa, Takahisa Furuta, Ken Sugimoto, Junichi Kawakami. Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders. Drug Metabolism and Pharmacokinetics 2024; 58: 101027 doi: 10.1016/j.dmpk.2024.101027
|
| 66 |
Su Young Kim, Duck Joo Choi, Jun-Won Chung. Antibiotic treatment for <italic>Helicobacter pylori</italic>: Is the end coming?. World Journal of Gastrointestinal Pharmacology and Therapeutics 2015; 6(4): 183-198 doi: 10.4292/wjgpt.v6.i4.183
|
| 67 |
D N Andreev, D T Dicheva, I V Maev. Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice. Terapevticheskii arkhiv 2017; 89(2): 84 doi: 10.17116/terarkh201789284-90
|
| 68 |
Nobuhiro Inatomi, Jun Matsukawa, Yuuichi Sakurai, Kazuyoshi Otake. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases. Pharmacology & Therapeutics 2016; 168: 12 doi: 10.1016/j.pharmthera.2016.08.001
|
| 69 |
Muhammad Miftahussurur, Dalla Doohan, Ari Fahrial Syam, Iswan Abbas Nusi, Phawinee Subsomwong, Langgeng Agung Waskito, Hasan Maulahela, Fardah Akil, Willy Brodus Uwan, Gontar Siregar, Kartika Afrida Fauzia, Yudith Annisa Ayu Rezkitha, Abdul Rahman, I Dewa Nyoman Wibawa, Alexander Michael Joseph Saudale, Marselino Richardo, Titong Sugihartono, Alvi Chomariyati, Taufan Bramantoro, Tomohisa Uchida, Yoshio Yamaoka. CYP2C19 Polymorphisms in Indonesia: Comparison among Ethnicities and the Association with Clinical Outcomes. Biology 2021; 10(4): 300 doi: 10.3390/biology10040300
|
| 70 |
Wolfgang Fischbach, Jan Bornschein, Jörg C. Hoffmann, Sibylle Koletzko, Alexander Link, Lukas Macke, Peter Malfertheiner, Kerstin Schütte, Dieter-Michael Selgrad, Sebastian Suerbaum, Christian Schulz. Update S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS). Zeitschrift für Gastroenterologie 2024; 62(02): 261 doi: 10.1055/a-2181-2225
|
| 71 |
Shailja C. Shah, Prasad G. Iyer, Steven F. Moss. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology 2021; 160(5): 1831 doi: 10.1053/j.gastro.2020.11.059
|
| 72 |
Ying Zhou, Ziqing Ye, Yuhuan Wang, Ye Zhang, Zifei Tang, Weili Yan, Yuan Jiang, Ying Huang. Comparison of four different regimens against Helicobacter pylori as a first‐line treatment: A prospective, cross‐sectional, comparative, open trial in Chinese children. Helicobacter 2020; 25(2) doi: 10.1111/hel.12679
|
| 73 |
Yingying Hu, Zhize Ye, Hualu Wu, Xiaohai Chen, Hailun Xia, Jian-ping Cai, Guo-xin Hu, Ren-ai Xu. Functional assessment of CYP3A4 and CYP2C19 genetic polymorphisms on the metabolism of clothianidin in vitro. Chemico-Biological Interactions 2024; 399: 111154 doi: 10.1016/j.cbi.2024.111154
|
| 74 |
Yi-Chung Lee, Yi-Chu Liao, Feng-Chi Chang, Hui-Chi Huang, Jui-Yao Tsai, Chih-Ping Chung. Investigating CYP2C19 loss-of-function allele statuses and their association with stroke of different etiologies in a Taiwanese population. Journal of the Chinese Medical Association 2019; 82(6): 469 doi: 10.1097/JCMA.0000000000000101
|
| 75 |
Xinyuan Han, Xiqiu Yu, Xiaojuan Gao, Xiangyu Wang, Chin Yen Tay, Xiaolan Wei, Bing Lai, Barry J. Marshall, Xiuming Zhang, Eng Guan Chua. Quantitative PCR of string‐test collected gastric material: A feasible approach to detect Helicobacter pylori and its resistance against clarithromycin and levofloxacin for susceptibility‐guided therapy. Helicobacter 2023; 28(4) doi: 10.1111/hel.12985
|
| 76 |
Denis S. Fedorinov, Karin B. Mirzaev, Dmitriy V. Ivashchenko, Ilyas I. Temirbulatov, Dmitriy A. Sychev, Nadezda R. Maksimova, Jana V. Chertovskih, Nyurguiana V. Popova, Ksenia S. Tayurskaya, Zoya A. Rudykh. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). Drug Metabolism and Personalized Therapy 2018; 33(2): 91 doi: 10.1515/dmpt-2018-0004
|
| 77 |
Ravishankar Ram M., Xinsheng Teh, Tamayanthi Rajakumar, Khean Lee Goh, Alex Hwong Ruey Leow, Bee Hoon Poh, Vanitha Mariappan, Esaki M Shankar, Mun Fai Loke, Jamuna Vadivelu. Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes ofHelicobacter pyloriisolates influence the outcome of triple therapy. Journal of Antimicrobial Chemotherapy 2019; 74(1): 11 doi: 10.1093/jac/dky401
|
| 78 |
Ying-Ying Han, Lin Zhou, Yun-Lian Hu, Xiang-Wu Ding, Hui Long, Fei Liu, Ming Xu, Zhen-Yu Zhang, Shuang-Ling Li, Qiu-Yan Wang, Cheng-Xia Su, Yan Chen, Jie Chen, Ya Lin, Pei-Yuan Li. Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study. Journal of Gastroenterology 2023; 58(12): 1167 doi: 10.1007/s00535-023-02042-2
|
| 79 |
Irina Yurievna Kolesnikova, Irina Vyacheslavovna Ivakhnenko, Anzhelika Viktorovna Ponomareva, Sergey Ivanovich Krayushkin. Modern aspects of eradication therapy. Spravočnik vrača obŝej praktiki (Journal of Family Medicine) 2020; (12): 36 doi: 10.33920/med-10-2012-05
|
| 80 |
Keliang Wang, Dandi Lou, Wei Dai, Rongrong Fu, Zhenhua Ma. Comparison of sequential therapy with concomitant therapy in first-line treatment of Helicobacter pylori: an updated meta-analysis.
Journal of Medical Microbiology
2022; 71(1) doi: 10.1099/jmm.0.001490
|
| 81 |
Luyi Chen, Jiamin He, Lan Wang, Qiwei Ge, Hua Chu, Yujia Chen, Xiaoli Chen, Yanqin Long, Yanyong Deng, Huiqin He, Aiqing Li, Shujie Chen. Efficacies of different proton pump inhibitor-based 14-day bismuth–furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial. Clinical and Experimental Medicine 2018; 18(4): 569 doi: 10.1007/s10238-018-0510-9
|